# US 2001/0056096 A1 · Hydrazones and analogs as cholesterol lowering agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0056096 A1
- Document ID: US20010056096A1
- Status: Published application
- Kind: A1
- Application number: 09/798,247
- Filed: 2001-03-01
- Published: 2001-12-27
- Earliest claimed: 2000-03-01
- Assignees: Tularik Inc.
- Inventors: Julio C. Medina; Hirohiko Hasegawa
- Web page: https://patentgrep.com/patent/US20010056096A1

## CPC

- C07D 207/325: with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07C 251/86: having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 215/12: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 215/14: Radicals substituted by oxygen atoms
- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 307/81: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 311/22: with oxygen or sulfur atoms directly attached in position 4
- C07D 333/58: Radicals substituted by nitrogen atoms
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Hydrazones and hydrazone analogs are provided which are useful as upregulators of LDL receptors and can be used in the treatment of hypercholesterolemia and related disorders and conditions.

## Claims

### Claim 1

A compound having the formula (I):
31
wherein
the subscript n is an integer of from 1 to 2;
the lowercase letters d and e are each independently selected from the group consisting of CH and N;
Q is selected from the group consisting of Ar1 C(R1)═N— and
32
wherein Ar1 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R1 is H or substituted or unsubstituted (C1-C4)alkyl, the lowercase letters a, b and c are each independently CH or N, each Z1 is independently selected from hydroxy, halogen, amino, nitro, cyano, substituted or unsubstituted monocyclic heterocycloalkyl, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C1-C10)alkoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted (C1-C8)acylamine, substituted or unsubstituted (C1-C8)alkylamine and substituted or unsubstituted di(C1-C8)alkylamine, and the subscript
m is an integer of from 1 to 4;
W is a member selected from the group consisting of NH, O, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
X is a member selected from the group consisting of S and —CH═CH—;
Y is a member selected from the group consisting of —CO2R′, —CH2OR′, —C(O)R′, —C(O)NR′R″ and —CH2NR′R″, wherein R′ and R″ are each members independently selected from the group consisting of hydrogen and (C1-C8)alkyl; and
each Z2 is a member independently selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, substituted or unsubstituted monocyclic heterocycloalkyl, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C1-C10)alkoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted (C1-C8)acylamine, substituted or unsubstituted (C1-C8)alkylamine and substituted or unsubstituted di(C1-C8)alkylamine.

### Claim 2 (depends on 1)

The compound of claim 1, having the formula (II):
33
wherein
Ar1 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R1 is H or substituted or unsubstituted (C1-C4)alkyl;
W is selected from the group consisting of NH and O; and
R1 is H or substituted or unsubstituted (C1-C4)alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, having the formula (III):
34
wherein
the subscript m is an integer of from 1 to 4;
the lowercase letters a, b and c are each independently selected from the group consisting of CH and N;
W is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; and
each Z1 is a member independently selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, substituted or unsubstituted monocyclic heterocycloalkyl, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C1-C10)alkoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted (C1-C8)acylamine, substituted or unsubstituted (C1-C8)alkylamine and substituted or unsubstituted di(C1-C8)alkylamine.

### Claim 4 (depends on 1)

A compound of claim 1, wherein Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″.

### Claim 5 (depends on 1)

A compound of claim 1, wherein X is —CH═CH—.

### Claim 6 (depends on 1)

A compound of claim 1, wherein X is —CH═CH— and Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″.

### Claim 7 (depends on 2)

A compound of claim 2, wherein X is —CH═CH—, Y is selected from the group consisting of —CO2R′ and —C(O)NR′R′, and Ar1 is selected from the group consisting of substituted or unsubstituted naphthyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted benzothienyl, substituted or unsubstituted indolyl, substituted or unsubstituted benzofuranyl, substituted or unsubstituted furanyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyrrolyl, and substituted or unsubstituted thiophene, substituted or unsubstituted naphthyridine, substituted or unsubstituted quinazolinyl, substituted or unsubstituted benzoimidazolyl, substituted or unsubstituted indolizinyl, substituted or unsubstituted quinoxalinyl, substituted or unsubstituted isoquinolinyl, substituted or unsubstituted pyridyl and substituted or unsubstituted pteridinyl.

### Claim 8 (depends on 7)

A compound of claim 7, wherein said substituents are selected from the group consisting of halogen, amino, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, phenyl, (C1-C6)haloalkylphenyl, phenoxy, benzyloxy, hydroxy(C1-C6)alkyl, (C1-C6)acylamino and mono or di(C1-C6)alkylamino.

### Claim 9 (depends on 2)

The compound of claim 2, wherein R1 is hydrogen, Y is selected from the group consisting of —CO2R and —C(O)NR′R″, and Ar1 is selected from the group consisting of substituted or unsubstituted naphthyl, substituted or unsubstituted quinolinyl and substituted or unsubstituted quinazolinyl.

### Claim 10 (depends on 2)

A compound of claim 2, wherein R1 is hydrogen, Y is selected from the group consisting of —CO2R and —C(O)NR′R″, and Ar1 is substituted or unsubstituted quinolinyl.

### Claim 11 (depends on 2)

A compound of claim 2, selected from the group consisting of
35

### Claim 12 (depends on 3)

A compound of claim 3, wherein Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″, and W is selected from the group consisting of substituted or unsubstituted furanyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted triazinyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyridazinyl, and substituted or unsubstituted thienyl.

### Claim 13 (depends on 3)

A compound of claim 3, wherein X is —CH═CH—, Y is selected from the group consisting Of —CO2R′ and —C(O)NR′R″, and W is selected from the group consisting of substituted or unsubstituted f,ranyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted triazinyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyridazinyl, and substituted or unsubstituted thienyl.

### Claim 14 (depends on 13)

A compound of claim 13, wherein each of said Z1 and Z2 substituents are independently selected from the group consisting of halogen, amino, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, phenyl, (C1-C6)haloalkylphenyl, phenoxy, benzyloxy, hydroxy(C1-C6)alkyu (C1-C6)acylamino and mono or di(C1-C6)alkylamino.

### Claim 15 (depends on 3)

A compound of claim 3, wherein d and e are each CH, a nd one of a, b or c is N.

### Claim 16 (depends on 15)

A compound of claim 15, wherein a is N and b, c, d and e are each CH.

### Claim 17 (depends on 3)

A compound of claim 3, selected from the group consisting of
36

### Claim 18

A composition comprising a pharmaceutically acceptable excipient and a compound having the formula (I):
37
wherein
the subscript nI is an integer of from 1 to 2;
the lowercase letters d and e are each independently selected from the group consisting of CH and N;
Q is selected fr om the group consisting of Ar1C(R1)═N— and
38
wherein Ar1 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R1 is H or substituted or unsubstituted (C1-C4)alkyl, the lowercase letters a, b and c are each independently CH or N, each Z1 is independently selected from hydroxy, halogen, amino, nitro, cyano, substituted or unsubstituted monocyclic heterocycloalkyl, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C1-C10)alkoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted (C1-C8)acylamine, substituted or unsubstituted (C1-C8)alkylamine and substituted or unsubstituted di(C1-C8)alkylamine, and the subscript
m is an integer of from 1 to 4;
W is a member selected from the group consisting of NH, O, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
X is a member selected from the group consisting of S and —CH═CH—;
Y is a member selected from the group consisting of —CO2R′, —CH2OR′, —C(O)R′, —C(O)NR′R″ and —CH2NR′R″, wherein R′ and R″ are each members independently selected from the group consisting of hydrogen and (C1-C8)alkyl; and
each Z2 is a member independently selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, substituted or unsubstituted monocyclic heterocycloalkyl, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C1-C10)alkoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted (C1-C8)acylamine, substituted or unsubstituted (C1-C8)alkylamine and substituted or unsubstituted di(C1-C8)alkylamine.

### Claim 19 (depends on 18)

A composition of claim 18, wherein said compound has the formula (II):
39
wherein
Ar1 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R1 is H or substituted or unsubstituted (C1-C4)alkyl;
W is selected from the group consisting of NH and O; and
R1 is H or substituted or unsubstituted (C1-C4)alkyl.

### Claim 20 (depends on 18)

A composition of claim 18, wherein said compound has the formula (III):
40
wherein
the subscript m is an integer of from 1 to 4;
the lowercase letters a, b and c are each independently selected from the group consisting of CH and N;
W is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; and
each Z1 is a member independently selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, substituted or unsubstituted monocyclic heterocycloalkyl, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C1-C10)alkoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted (C1-C8)acylamine, substituted or unsubstituted (C1-C8)alkylamine and substituted or unsubstituted di(C1-C8)alkylamine.

### Claim 21 (depends on 18)

A composition of claim 18, wherein Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″.

### Claim 22 (depends on 18)

A composition of claim 18, wherein X is —CH═CH—.

### Claim 23 (depends on 18)

A composition of claim 18, wherein X is —CH═CH— and Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″.

### Claim 24 (depends on 19)

A composition of claim 19, wherein X is —CH═CH—, Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″, and Ar1 is selected from the group consisting of substituted or unsubstituted naphthyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted benzothienyl, substituted or unsubstituted indolyl, substituted or unsubstituted benzofuranyl, substituted or unsubstituted faranyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyrrolyl, and substituted or unsubstituted thiophene, substituted or unsubstituted naphthyridine, substituted or unsubstituted quinazolinyl, substituted or unsubstituted benzoimidazolyl, substituted or unsubstituted indolizinyl, substituted or unsubstituted quinoxalinyl, substituted or unsubstituted isoquinolinyl, substituted or unsubstituted pyridyl and substituted or unsubstituted pteridinyl.

### Claim 25 (depends on 24)

A composition of claim 24, wherein said substituents are selected from the group consisting of halogen, amino, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, phenyl, (C1-C6)haloalkylphenyl, phenoxy, benzyloxy, hydroxy(C1-C6)alkyl, (C1-C6)acylamino and mono or di(C1-C6)alkylamino.

### Claim 26 (depends on 19)

A composition of claim 19, wherein R1 is hydrogen, Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″, and Ar1 is selected from the group consisting of selected from the group consisting of substituted or unsubstituted naphthyl, substituted or unsubstituted quinolinyl and substituted or unsubstituted quinazolinyl.

### Claim 27 (depends on 19)

A composition of claim 19, wherein R1 is hydrogen, Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″, and Ar1 is selected from the group consisting of substituted or unsubstituted quinolinyl.

### Claim 28 (depends on 19)

A composition of claim 19, wherein said compound is selected from the group consisting of:
41

### Claim 29 (depends on 20)

A composition of claim 20, wherein X is —CH═CH—, Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″, and W is selected from the group consisting of substituted or unsubstituted furanyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted triazinyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyridazinyl, and substituted or unsubstituted thienyl.

### Claim 30 (depends on 29)

A composition of claim 29, wherein each of said Z1 and Z2 substituents are independently selected from the group consisting of halogen, amino, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, phenyl, (C1-C6)haloalkylphenyl, phenoxy, benzyloxy, hydroxy(C1-C6)alkyl, (C1-C6)acylamino and mono or di(C1-C6)alkylamino.

### Claim 31 (depends on 20)

A composition of claim 20, wherein d and e are each CH, and one ofa,borcisN.

### Claim 32 (depends on 31)

A composition of claim 31, wherein a is N and b, c, d and e are each CH.

### Claim 33 (depends on 20)

A composition of claim 20, wherein said compound is selected from the group consisting of
42

### Claim 34 (depends on 18)

A composition in accordance with claim 18, further comprising a second hypolipidemic agent.

### Claim 35 (depends on 34)

A composition in accordance with claim 34, wherein said second hypolipidemic agent is selected from the group consisting of bile acid sequestrants, nicotinic acid and its derivatives, HMG-CoA reductase inhibitors, fibric acids, probucol, raloxifene and its derivatives, and combinations thereof.

### Claim 36 (depends on 28)

A composition in accordance with claim 28, further comprising a second hypolipidemic agent.

### Claim 37 (depends on 34)

A composition in accordance with claim 34, further comprising a second hypolipidemic agent.

### Claim 38 (depends on 18)

A composition in accordance with claim 18, wherein the amount of said compound and said agent is from {fraction (1/100)} to ¼ of the normal individual therapeutic doses.

### Claim 39 (depends on 18)

A composition in accordance with claim 18, wherein the amount of said compound and said agent is from {fraction (1/10)} to ¼ of the normal individual therapeutic doses.

### Claim 40

A method of treating a disease or condition selected from the group consisting of hypercholesterolemia, hyperlipidemia and other metabolic disorders associated with abnormally high levels of lipoproteins, cholesterol or triglycerides, said method comprising administering to a subject in need of such treatment an effective amount of a compound having the formula (I):
43
wherein
the subscript n is an integer of from 1 to 2;
the lowercase letters d and e are each independently selected from the group consisting of CH and N;
Q is selected from the group consisting of Ar1 C(R1)═N— and
44
wherein Ar1 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R1 is H or substituted or unsubstituted (C1-C4)alkyl, the lowercase letters a, b and c are each independently CH or N, each Z1 is independently selected from hydroxy, halogen, amino, nitro, cyano, substituted or unsubstituted monocyclic heterocycloalkyl, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C1-C10)alkoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted (C1-C8)acylamine, substituted or unsubstituted (C1-C8)alkylamine and substituted or unsubstituted di(C1-C8)alkylamine, and the subscript m is an integer of from 1 to 4;
W is a member selected from the group consisting of NH, O, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
X is a member selected from the group consisting of S and —CH═CH—;
Y is a member selected from the group consisting of —CO2R′, —CH2OR′, —C(O)R′, —C(O)NR′R″ and —CH2NR′R″, wherein R′ and R″ are each members independently selected from the group consisting of hydrogen and (C1-C8)alkyl; and
each Z2 is a member independently selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, substituted or unsubstituted monocyclic heterocycloalkyl, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C1-C10)alkoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted (C1-C8)acylamine, substituted or unsubstituted (C1-C8)alkylamine and substituted or unsubstituted di(C1-C8)alkylamine.

### Claim 41 (depends on 40)

A method in accordance with claim 40, wherein said compound has the formula (II):
45
wherein
Ar1 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R1 is H or substituted or unsubstituted (C1-C4)alkyl;
W is selected from the group consisting of NH and O; and
R1 is H or substituted or unsubstituted (C1-C4)alkyl.

### Claim 42 (depends on 40)

A method in accordance with claim 40, wherein said compound has the formula (III):
46
wherein
the subscript m is an integer of from 1 to 4;
the lowercase letters a, b and c are each independently selected from the group consisting of CH and N;
W is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; and
each Z1 is a member independently selected from the group consisting of hydroxy, halogen, amino, nitro, cyano, substituted or unsubstituted monocyclic heterocycloalkyl, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C1-C10)alkoxy, substituted or unsubstituted benzyloxy, substituted or unsubstituted (C1-C8)acylamine, substituted or unsubstituted (C1-C8)alkylamine and substituted or unsubstituted di(C1-C8)alkylamine.

### Claim 43 (depends on 40)

A method in accordance with claim 40, wherein X is —CH═CH—.

### Claim 44 (depends on 40)

A method in accordance with claim 40, wherein X is —CH═CH—.

### Claim 45 (depends on 40)

A method in accordance with claim 40, wherein X is —CH═CH— and Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″.

### Claim 46 (depends on 41)

A method in accordance with claim 41, wherein X is —CH═CH— and Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″, and Ar1 is selected from the group consisting of substituted or unsubstituted naphthyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted benzothienyl, substituted or unsubstituted indolyl, substituted or unsubstituted benzofuranyl, substituted or unsubstituted furanyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyrrolyl, and substituted or unsubstituted thiophene, substituted or unsubstituted naphthyridine, substituted or unsubstituted quinazolinyl, substituted or unsubstituted benzoimidazolyl, substituted or unsubstituted indolizinyl, substituted or unsubstituted quinoxalinyl, substituted or unsubstituted isoquinolinyl, substituted or unsubstituted pyridyl and substituted or unsubstituted pteridinyl.

### Claim 47 (depends on 46)

A method in accordance with claim 46, wherein said substituents are selected from the group consisting of halogen, amino, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, phenyl, (C1-C6)haloalkylphenyl, phenoxy, benzyloxy, hydroxy(C1-C6)alkyl, (C1-C6)acylamino and mono or di(C1-C6)alkylamino.

### Claim 48 (depends on 41)

A method in accordance with claim 41, wherein RI is hydrogen, Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″, and Ar1 is selected from the group consisting of substituted or unsubstituted naphthyl, substituted or unsubstituted quinolinyl and substituted or unsubstituted quinazolinyl.

### Claim 49 (depends on 41)

A method in accordance with claim 41, wherein RI is hydrogen, Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″, and Ar1 is selected from the group consisting of substituted or unsubstituted quinolinyl.

### Claim 50 (depends on 41)

A method in accordance with claim 41, wherein said compound is selected from the group consisting of:
47

### Claim 51 (depends on 42)

A method in accordance with claim 42, wherein X is —CH═CH—, Y is selected from the group consisting of —CO2R′ and —C(O)NR′R″, and W is selected from the group consisting of substituted or unsubstituted furanyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted triazinyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyridazinyl, and substituted or unsubstituted thienyl.

### Claim 52 (depends on 51)

A method in accordance with claim 51, wherein each of said Z1 and Z2 substituents are independently selected from the group consisting of halogen, amino, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, phenyl, (C1-C6)haloalkylphenyl, phenoxy, benzyloxy, hydroxy(C1-C6)alkyl, (C1-C6)acylamino and mono or di(C1-C6)alkylamino.

### Claim 53 (depends on 42)

A method in accordance with claim 42, wherein d and e are each CH, and one of a, b or c isN.

### Claim 54 (depends on 42)

A method in accordance with claim 42, wherein a is N, each of b, c, d and e are CH, and W is unsubstituted phenyl.

### Claim 55 (depends on 42)

A method in accordance with claim 42, wherein said compound is selected from the group consisting of
48

### Claim 56 (depends on 40)

A method in accordance with claim 40, wherein said compound is admninistered in combination with a second hypolipidemic agent.

### Claim 57 (depends on 56)

A method in accordance with claim 56, wherein said second hypolipidemic agent is selected from the group consisting of bile acid sequestrants, nicotinic acid and its derivatives, HMG-CoA reductase inhibitors, fibric acids, probucol, raloxifene and its derivatives, and combinations thereof.

### Claim 58 (depends on 41)

A method in accordance with claim 41, wherein said compound is administered in combination with a second hypolipidemic agent.

### Claim 59 (depends on 42)

A method in accordance with claim 42, wherein said compound is administered in combination with a second hypolipidemic agent.

### Claim 60 (depends on 40)

A method in accordance with claim 40, wherein said compound and said second hypolipidemic agent are administered sequentially.
